安心交易
不成功退款，无后顾之忧，风险服务升级。Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.Expert Review of Clinical Pharmacology (ISSN 1751-2433) provides a forum for informed debate and critical analysis of all aspects of safety, tolerability, efficacy and therapeutic applications, in addition to covering toxicity issues, adverse reactions, pharmacoeconomics and societal issues.Coverage includes:? ADME studies and PK/PD modeling ? Novel clinical trial design and conduct ? Toxicity and carcinogenesis ? Adverse effects/reactions, drug–drug and drug–disease interactions ? Pharmacogenetics, genomics and the incorporation of new biomarkers in drug development and clinical practice ? Translational medicine ? Pharmacoepidemiology, risk management and pharmacovigilance ? Pharmacotherapy in specific patient groups, such as children, women, the immunocompromised ? Pharmacology and ethnicity ? Impact on quality of life and pharmacoeconomic issues ? Regulation of drug development and marketing ? Epidemiology and biostatisticsExpert Review of Clinical Pharmacology bridges the gap between the medical profession, clinical research and the pharmaceutical industry, providing clinical and pharmaceutical researchers, drug development specialists, physicians and other healthcare professionals with the key information they need to assist in the progress of pharmacological therapy.All reviews are subject to rigorous peer review in association with our independent panel of Editorial Board members, representing the key experts in their pharmacological specialties.
药物开发技术的进步正在产生创新的新疗法，从潜在的救生药物到生活方式产品。然而，近年来，开发新药的成本猛增，人们对耐药性和药物经济学的担忧也日益突出。在临床试验阶段出现的不良反应不断提醒人们严格的安全性和毒性测试的重要性。此外，药物基因组学和“个性化”治疗方法的出现，将需要一种新的药物评估和医疗保健提供方法。临床药理学在整合所有在现代生物医学实践中积极应对此类挑战的专家和参与者的专业知识方面发挥着重要作用。临床药理学专家评审（ISSN1751-2433）为安全性、耐受性、疗效和治疗应用的所有方面的知情辩论和关键分析提供了一个论坛，并涵盖毒性问题、不良反应、药理学和社会问题。覆盖范围包括：?ADME研究和PK/PD建模?新颖的临床试验设计和实施?毒性和致癌作用?不良反应/反应、药物-药物和药物-疾病相互作用?药物遗传学、基因组学以及在药物开发和临床实践中加入新的生物标志物?转化医学?药物流行病学、风险管理和药物警戒?针对特定患者群体的药物治疗，如儿童、妇女，免疫功能受损?药理学和种族?对生活质量和药物经济问题的影响?药品开发和营销法规?流行病学和生物统计学临床药理学专家评审弥合了医疗专业、临床研究和制药行业之间的差距，为临床和药物研究人员、药物开发专家、医生和其他保健专业人员提供了他们需要的关键信息，以协助药物治疗的进展。所有的评论都需要与我们独立的编辑委员会成员进行严格的同行评审，代表他们药理学专业的关键专家。
安心交易
不成功退款，无后顾之忧，风险服务升级。
合规备案认证机构
资质许可齐全，合规经营，用户权益有保障。
正刊保障
刊物在国家新闻出版署网可查，抵制假刊、增刊。
对公账户资金监管
交易均通过对公账户，资金安全有保障。01 选择服务并上传稿件 我们的学术顾问将根据您的需求推荐适合的服务
02 分配资深编辑和同行专家 根据您的服务方案和研究方向，为您分配资深编辑和同行专家
03 交付及反馈 每个环节的服务会在您审阅和确认后进行下一步，根据您的反馈和建议做调整
04 提升稿件质量 我们将基于您的反馈并平衡期刊的投稿要求，为您进一步优化稿件
05 提交投稿 出版专家将在您确认定稿后，为您整理并检查所有必须文件，协助您完成期刊投稿。
06 投稿跟进 及时查询稿件状态，协助您与期刊编辑沟通，根据审稿意见协助修正文章
07 拒稿支持 若期刊拒稿，您可通过拒稿咨询服务发掘稿件的改进方案，并获取365天无限次向同期刊或其他期刊的重投服务
